Key Dates

Related Announcements

• March 01, 2024 - Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed). See NOFO RFA-MD-24-005. 

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that effective immediately the National Heart, Lung, and Blood Institute (NHLBI) will participate in RFA-MD-24-005 “Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)”. 

The following text has been added in bold and italics to reflect NHLBI's participation:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Minority Health and Health Disparities (NIMHD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Heart, Lung, and Blood Institute (NHLBI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Sexual and Gender Minority Research Office (SGMRO)

Assistance Listing Number(s)

93.307, 93.847, 93.837, 93.838, 93.839, 93.840, 93.233

Part 2. Section I. Funding Opportunity Description

NHLBI is seeking applications focusing on HIV-associated (non-AIDS) comorbidities and co-infections where at least one co-occurring heart, lung, blood, or sleep (HLBS) condition impacts people living with HIV (PWH) experiencing health disparities. The purpose of this initiative is to support research to determine the underlying mechanisms that contribute to health disparities in HIV and aging and how multiple comorbidities influence overall health outcomes and quality of life (QoL) among PWH from populations that experience health disparities.  NHLBI strongly encourages multilevel proposals to ascertain the mechanism influencing HLBS diseases and associated conditions. Further, opportunities to actively collaborate with community partners and those with lived experiences that would inform the development, implementation, and analysis of the proposals are strongly encouraged.

Areas of research interest may include but are not limited to:

• Address the interplay of multiple factors including social factors with microbiome, epigenomics, and proteomics to identify risk patterns for HIV-associated HLBS comorbidities.
• Identify resiliency factors to reduce sleep, pulmonary and hematological comorbidity risks and improve QoL and health outcomes in diverse settings, especially rural settings.
• Investigate the effects of climate change on HIV-associated HLBS conditions.
• Examine the influence of social determinants of health on immune responses with various social stressors and stigma on disease outcomes.
• Studies on HIV and co-infections (e.g., CMV, HCV) and how they collectively affect HIV-associated HLBS comorbidities and health-related quality of life in PWH experiencing health disparities.
• Studies examining interplay of multilevel factors (i.e., individual, interpersonal, community, societal) and how they affect multiple comorbidities in PWH with intersecting identities in diverse settings, especially rural settings.
• Studies examining how behavioral factors (such as alcohol consumption, substance use and smoking) and HIV-associated HLBS comorbidity burden contribute to disparities in HIV and aging in PWH experiencing health disparities.
• Patient-, clinician-, and system/policy-level factors that predict receipt of appropriate HIV-associated HLBS treatments for co-occurring multiple comorbidities in PWH experiencing health disparities.
• Studies focused on HIV and women in minority populations with HIV-associated HLBS comorbidities, including, but not limited to addressing access to care, stigma, discrimination, gender-based violence and intimate partner violence in cis-and transgender women.
• Studies focused on using community-based participatory research methods while addressing clinical and patient-centered outcomes in PWH with multiple comorbidities from populations that experience health disparities in diverse settings, especially rural settings.
• Novel biomarker studies to identify HIV-associated HLBS disease signatures across the lifespan.
• Mechanistic studies to assess the role of chronic immune activation as a significant mediator of the development of HIV-associated HLBS conditions. 

Applications that are NOT responsive to this RFA include the following:

• Studies without either human subjects research or human clinical samples
• Studies that are focused on only animal studies
• Studies that do not have a primary focus on HIV-related HLBS comorbidities
• Studies whose sole purpose is to assess prevalence of comorbidities in specific populations
• Studies that do not focus on PWH U.S. populations that experience health disparities
• Clinical trials

Section VII. Agency Contacts

Scientific/Research Contact(s)

Mary Masterson, PhD, MS
National Heart, Lung, and Blood Institute (NHLBI)
Center for Translation Research and Implementation Science (CTRIS)
Telephone: 301-827-6113  
Email: [email protected]

Financial/Grants Management Contact(s)

Lynn Rundhaugen
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-480-4546
Email: [email protected] 

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

Mary Masterson, PhD, MS
National Heart, Lung, and Blood Institute (NHLBI)
Center for Translation Research and Implementation Science (CTRIS)
Telephone: 301-827-6113  
Email: [email protected]

Financial/Grants Management Contact(s)

Lynn Rundhaugen
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-480-4546
Email: [email protected]